Foundayo vs Rybelsus: Two Daily GLP-1 Pills, Different Molecules, Different Jobs

The short answer

Foundayo and Rybelsus get compared because they look alike on a pharmacy shelf: a tablet, once a day, that activates the GLP-1 receptor. In practice they solve different problems for different patients.

One more thing to know before you read further: in the U.S., Novo Nordisk is retiring the Rybelsus brand name. The FDA approved "Ozempic" as the proprietary name for Novo's oral semaglutide tablets on February 4, 2026, and the reformulated "Ozempic pill" launched in the U.S. on May 4, 2026. The current FDA label covers both Rybelsus tablets (3, 7 and 14 mg) and Ozempic tablets (1.5, 4 and 9 mg). Same molecule and same indications. The strengths are not interchangeable milligram for milligram. Where this guide says "Rybelsus," read it as "oral semaglutide for type 2 diabetes, under either name."

Two molecules, two engineering problems

Semaglutide is a peptide, a chain of amino acids modeled on the body's own GLP-1 hormone. Peptides are normally broken down in the stomach, which is why most semaglutide is injected. Rybelsus gets around this with an absorption enhancer and a very particular way of taking it. That is where the fasting rule comes from (more on that below).

Orforglipron is not a peptide. Lilly describes it as a small-molecule, non-peptide GLP-1 receptor agonist that is chemically synthesized, not built from amino acids. It binds to and activates the human GLP-1 receptor. Lilly's medical information page reports that in a phase 1 study, about 79% of a single 0.8 mg dose reached circulation. Because it does not depend on an empty stomach to be absorbed, Foundayo's label allows dosing with or without food.

So both pills land on the same receptor. They get there by very different routes, and the route drives the daily experience.

What each is approved to treat

Two practical consequences follow. First, Foundayo is not FDA-approved for type 2 diabetes. In a February 26, 2026 release, Lilly said a U.S. type 2 diabetes submission was planned for later in 2026. We could not confirm a submission or an FDA decision as of this writing. Second, prescribing Rybelsus mainly for weight loss in someone without diabetes is off-label. Insurers (and Medicare) usually tie coverage to the approved indication.

If weight management is the goal and you don't have diabetes, the oral semaglutide product that is FDA-approved for it is a different one: Wegovy tablets. We compare those two semaglutide pills in Wegovy pill vs. Rybelsus.

Dosing rules: fasting vs. none

This is the difference patients notice from day one. Everything below comes from the current FDA labels. Your prescriber's instructions take priority.

Rybelsus and Ozempic tablets

• One tablet, once daily, in the morning on an empty stomach.
• Take it with no more than 4 ounces of plain water. No other liquids.
• Wait at least 30 minutes before eating, drinking or taking any other oral medicine.
• Swallow whole. Do not split, crush or chew.
• The first strength (3 mg Rybelsus or 1.5 mg Ozempic tablet) is a 30-day starter dose. The label notes it is not effective for blood sugar control. The dose steps up after 30 days and may increase again after day 60 if more control is needed.
• Missed dose: skip it and take the next dose the following day.

Foundayo

• One tablet, once daily, at any time of day, with or without food. Swallow whole.
• Starts at 0.8 mg. After at least 30 days it goes to 2.5 mg, then after at least 30 more days to 5.5 mg. After at least 30 days at each step, your prescriber may increase it to 9, 14.5 or 17.2 mg (the maximum).
• Missed dose: take it as soon as possible, but never two in one day. If you miss 7 or more days in a row, the label says escalation restarts at a lower dose, so call your prescriber.

More detail on getting the semaglutide routine right is in our guide on how to take oral semaglutide correctly.

What the trials show

Head-to-head: ACHIEVE-3

The most direct comparison is Lilly's ACHIEVE-3 trial (results announced February 26, 2026, and published in The Lancet). It ran 52 weeks and was randomized but open-label, so participants knew which drug they were taking. It enrolled 1,698 adults with type 2 diabetes who weren't well controlled on metformin. They were assigned to orforglipron 12 or 36 mg, or oral semaglutide 7 or 14 mg. Average starting A1C was 8.3%.

Source: Eli Lilly press release, Feb. 26, 2026. The trial's orforglipron doses were capsules. Lilly says the 12 mg and 36 mg capsules correspond to the 9 mg and 17.2 mg Foundayo tablets sold in the U.S., and that capsules and tablets aren't interchangeable mg for mg. The oral semaglutide doses match the original Rybelsus strengths.

Two honest caveats. Orforglipron lowered A1C and weight more, and more people on it stopped because of side effects. And because Foundayo isn't FDA-approved for type 2 diabetes, these results describe a use that isn't on its U.S. label yet.

Each drug's own approval evidence

Foundayo was approved on two 72-week placebo-controlled trials. In adults with obesity or overweight without diabetes (3,127 people), average weight change at the 17.2 mg dose was −11.1%, versus −2.1% on placebo. In adults with type 2 diabetes and a BMI of 27 or higher (1,613 people), it was −9.6% versus −2.5%. These are the label's intention-to-treat figures. Lilly also cites a higher 12.4% figure for people who stayed on treatment.

Rybelsus trials measured blood sugar. In the label's monotherapy trial, A1C fell 1.2 points on 7 mg and 1.4 points on 14 mg, versus 0.3 points on placebo, at 26 weeks. Rybelsus also has a cardiovascular outcomes result. In the SOUL trial (14 mg, median follow-up about four years), major cardiovascular events occurred in 12.0% of participants versus 13.8% on placebo. That result supports its heart-risk indication in type 2 diabetes. Foundayo has no completed cardiovascular outcomes trial on its label.

Side effects and interactions

Both drugs mostly cause gastrointestinal side effects, which are most common while doses are going up. Both carry a boxed warning about thyroid C-cell tumors. They are contraindicated if you or a family member has had medullary thyroid carcinoma, or if you have MEN 2.

• Foundayo (pooled weight trials): nausea in 26–35% of people depending on dose, versus 10% on placebo; constipation 20–27% vs. 9%; diarrhea 21–25% vs. 11%; vomiting 13–24% vs. 4%. About 8% stopped because of side effects, versus 3% on placebo.
• Rybelsus (placebo-controlled diabetes trials): nausea in 11% at 7 mg and 20% at 14 mg, versus 6% on placebo; abdominal pain 10–11% vs. 4%; diarrhea 9–10% vs. 4%.

Those rates come from different trial populations, so don't compare them directly. ACHIEVE-3 is the only like-for-like comparison, and the drop-out figures are in the table above.

For a week-by-week view of what to expect, see our oral GLP-1 side-effects timeline.

Cost and access (October 2026)

Both manufacturers now sell self-pay tablets directly. These prices are what the manufacturers listed when we checked in October 2026. They change often, so confirm at checkout.

*LillyDirect lists the 2.5 mg and 5.5 mg prices as temporarily reduced through December 31, 2026. NovoCare lists Ozempic tablets also in 2- and 3-month quantities. We didn't find a separate current self-pay price for Rybelsus-branded tablets, which are being phased out in the U.S. Self-pay programs are not insurance.

• Commercial insurance: both companies advertise savings cards that can bring eligible copays down to as little as $25. Both exclude people with government coverage such as Medicare or Medicaid.
• Medicare: Part D can cover oral semaglutide for type 2 diabetes, subject to each plan's formulary. Foundayo has no diabetes indication. For weight management, it is one of the drugs in the temporary Medicare GLP-1 Bridge, which charges a $50 copay for eligible enrollees from July 1, 2026, through December 31, 2027. People with type 2 diabetes are excluded from the Bridge. Coverage basics are in our 2026 insurance coverage guide.

Our pricing hub and cost with and without insurance guide cover the whole field.

Who each one fits

If neither fits cleanly, for example weight management without diabetes but with established heart disease, the Wegovy pill has its own label and its own evidence. See Wegovy pill vs. Foundayo and our comparison tool.

Side-by-side table

This guide is general information, not medical advice. Your prescriber and pharmacist know your history; follow their instructions and the current FDA-approved label.